Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25091475 | 0.88 | — | — | |
| Hydrochloric Acid SCHEMBL19031032 | 0.88 | EPHX1 (0.34) | EPHX1 | |
| SCHEMBL17780178 | 0.78 | — | — | |
| SCHEMBL7120999 | 0.77 | — | — | |
| SCHEMBL422018 | 0.75 | — | — | |
| SCHEMBL420704 | 0.75 | — | — | |
| SCHEMBL420729 | 0.74 | DPP4 (0.37) | EPHX1 | |
| SCHEMBL419801 | 0.73 | DPP4 (0.34) | — | |
| SCHEMBL420711 | 0.73 | DPP4 (0.34) | — | |
| SCHEMBL421003 | 0.73 | DPP4 (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9879025-B2 | Transfer hydrogenation of cyclopamine analogs | INFINITY PHARMACEUTICALS, INC. (US) | 2018-01-30 | — | — | US | disclosed |
| US-20170029433-A1 | TRANSFER HYDROGENATION OF CYCLOPAMINE ANALOGS | ROYALTY SECURITY, LLC | 2017-02-02 | — | — | US | disclosed |
| US-9394313-B2 | Transfer hydrogenation of cyclopamine analogs | INFINITY PHARMACEUTICALS, INC. (US) | 2016-07-19 | — | — | US | disclosed |
| US-9376447-B2 | Transfer hydrogenation of cyclopamine analogs | INFINITY PHARMACEUTICALS, INC. (US) | 2016-06-28 | — | — | US | disclosed |
| US-20120065400-A1 | Transfer Hydrogenation of Cyclopamine Analogs | INFINITY PHARMACEUTICALS, INC. (US) | 2012-03-15 | — | — | US | disclosed |
| US-20120065399-A1 | Transfer Hydrogenation of Cyclopamine Analogs | INFINITY PHARMACEUTICALS, INC. (US) | 2012-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065400-A1 | Transfer Hydrogenation of Cyclopamine Analogs | HVCN1, KCNQ4, KCNQ5 | EPHX1 3510/4885 |
| US-20120065399-A1 | Transfer Hydrogenation of Cyclopamine Analogs | HVCN1, KCNQ4, KCNQ5 | EPHX1 3510/4885 |
| US-20170029433-A1 | TRANSFER HYDROGENATION OF CYCLOPAMINE ANALOGS | HVCN1, KCNQ4, KCNQ5 | EPHX1 3510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.